Neuroeconomics of Social Behavior Following Trauma Exposure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03383536 |
Recruitment Status :
Recruiting
First Posted : December 26, 2017
Last Update Posted : March 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Posttraumatic Stress Disorder |
Impaired social functioning is a frequent and disabling sequela of trauma-related disorders. PTSD is associated with a high rate of severe impairment in quality of life relative to other anxiety disorders, including panic disorder, social phobia, and OCD, with particularly marked impairment in social quality of life. Mounting evidence indicates that impairment in quality of life in PTSD is strongly related to its effect on social functioning. Such difficulties are widespread and affect multiple social networks, including marital relationships, and friendships and family relationships. Social withdrawal, defined here in terms of reduced social network size, is of particular interest because of its strong relationship with health outcomes, including increased risk of disability, reduced immune response, and increased mortality risk; most critically, poor social integration is associated with a threefold increase in suicide risk. Because women are at a 2.3-to-3-fold increased risk compared to men of developing PTSD following trauma, understanding the differential neurobiological pathways that may contribute to the development of stress-related disorders in women is particularly critical. Women are more likely than men to endorse social detachment following trauma, especially when the trauma involves exposure to violence.
In this project, we propose abnormal reward processing (anhedonia) as a specific mechanism underlying social withdrawal in trauma-exposed women, and we present a paradigm that capitalizes on advances in neuroeconomics to elucidate the neural underpinnings of social withdrawal. Additionally, we propose to identify the possible influences of a stress peptide (pituitary adenylate cyclase-activating polypeptide: PACAP) implicated in sex-specific changes in social behavior following stress exposure.
Study Type : | Observational |
Estimated Enrollment : | 168 participants |
Observational Model: | Case-Control |
Time Perspective: | Cross-Sectional |
Official Title: | Social Withdrawal Following Trauma Exposure: a Neuroeconomic Approach |
Actual Study Start Date : | November 14, 2017 |
Estimated Primary Completion Date : | August 31, 2022 |
Estimated Study Completion Date : | August 31, 2022 |

Group/Cohort |
---|
Phase 1
Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
|
Phase 2: PTS-SA
posttraumatic spectrum-socially anhedonic
|
Phase 2: PTS-nonSA
posttraumatic spectrum-non-socially anhedonic
|
Phase 2: HC
healthy controls
|
- Group differences in neuroeconomic game performance [ Time Frame: Measured on the day of the MRI scan ]Compared to the PTS-nonSA and HC groups, the PTS-SA group will demonstrate lower investments and slower learning rates on the Trust Task than on the non-social risk task compared with PTS-nonSA and HC subjects
- Group differences in fMRI BOLD signal [ Time Frame: Measured on the day of the MRI scan ]The HC and PTS-nonSA groups will show greater ventral striatum (VS), dorsal striatum (DS), and medial prefrontal cortex (mPFC) responses during the outcome phase of the trust game for 'share' versus baseline, compared to the PTS-SA group, for the real partner condition (Trust Task), but not for the risk task.
- Correlations between behavior and fMRI BOLD signal [ Time Frame: Measured on the day of the MRI scan ]Because social withdrawal will occur in response to reduced social reward value, we hypothesize that across the PTS groups, reduced VS, DS, and mPFC activity during the outcome phase of the trust game for 'share' outcomes will be associated with lower Trust Task investments, greater self-reported social anhedonia, and smaller social network size.
- PACAP correlations [ Time Frame: Measured on the day of the MRI scan ]Elevated PACAP levels will be associated with lower investments on the Trust Task; decreased social reward signals during the outcome phase for 'share' outcomes in the VS, DS, and mPFC; and smaller social network size.
- Mediation analysis [ Time Frame: Measured on the day of the MRI scan ]Within the PTS groups, decreased VS, DS, and mPFC response to 'share' outcomes will mediate the relationship between social anhedonia and reduced social network size.
- Functional connectivity (psychophysiological interaction) [ Time Frame: Measured on the day of the MRI scan ]PTS individuals with higher self-reported social anhedonia and social withdrawal will show reduced VS-mPFC connectivity for social rewards on the Trust Task.
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Phase 1 will include healthy volunteers (age 18-45, n = 60).
Phase 2 will include posttraumatic spectrum-socially anhedonic women (PTS-SA, n = 36), posttraumatic spectrum-non-socially anhedonic women (PTS-nonSA), and healthy controls (HC, n = 36).
Phase 1:
Inclusion Criteria:
- Age 18-45
- Self-reported healthy volunteer status
Exclusion Criteria:
- Inability to provide written informed consent in English
- Inability to see task due to visual impairment
- Participants who produce T-scores of 65 or higher on any Brief Symptom Inventory (BSI) subscales will not be eligible to remain in the Trust Task participant pool.
Phase 2:
Inclusion Criteria:
- Female
- Trauma exposure appropriate to group
- For trauma-exposed groups the index trauma is actual or threatened physical assault or sexual violence
- PCL-5 score 33 and above (for PS-SA and PS-nonSA groups)
- Right handedness
- Age 18-45
- English as a first language
Exclusion Criteria:
- History of neurological illness (including head injury with loss of consciousness > 5 minutes)
- Medical conditions that may influence neuroimaging (e.g. HIV)
- Current or past DSM-5 Axis I disorder (for HC group)
- History of bipolar disorder or schizophrenia spectrum disorder
- Contraindications for MRI
- Alcohol dependence in the past 5 years
- Substance dependence in the past 3 years
- Daily substance use in the past year
- Prescribed psychotropic medication use in the past month
- Wechsler Abbreviated Scale of Intelligence- Second Edition (WASI-II) FSIQ < 70.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03383536
Contact: Elizabeth Olson, PhD | 617-855-2268 | adlab@partners.org |
United States, Massachusetts | |
McLean Hospital | Recruiting |
Belmont, Massachusetts, United States, 02478 | |
Contact: Elizabeth Olson, PhD 617-855-2268 adlab@partners.org |
Principal Investigator: | Elizabeth Olson, PhD | Mclean Hospital |
Documents provided by Elizabeth Olson, Mclean Hospital:
Responsible Party: | Elizabeth Olson, Instructor, Mclean Hospital |
ClinicalTrials.gov Identifier: | NCT03383536 |
Other Study ID Numbers: |
2017P001423 K23MH112873-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | December 26, 2017 Key Record Dates |
Last Update Posted: | March 10, 2021 |
Last Verified: | March 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | We will evaluate requests for deidentified data on a case-by-case basis. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
fMRI stress peptide social neuroimaging |
Stress Disorders, Post-Traumatic Stress Disorders, Traumatic Trauma and Stressor Related Disorders Mental Disorders |